Anaplastic thyroid cancer: current capabilities of an oncologist
https://doi.org/10.17650/2222-1468-2023-13-1-116-125
Abstract
Continuous development of oncology as a science in the last decades and years led to noticeable improvement in treatment outcomes for patients with various malignant tumors. Diagnostics, surgery, radiotherapy significantly contributed to this improvement, however they cannot be compared to the progress achieved through advancements in our knowledge of genetic structure of tumors and subsequent advancements in pharmacology which allowed to achieve qualitatively better survival in oncological patients. These advancements did not leave out such a serious and highly lethal, though fortunately rare, disease as anaplastic thyroid cancer. This article is dedicated to the possibilities of using checkpoint inhibitors in treatment of this pathology to increase expected life span of the patients.
About the Authors
A. L. Pylev
Center for Innovative Medical Technologies
Russian Federation
Russian Federation
22B Dukhovskoy pereulok, Moscow 115191
D. S. Romanov
Center for Innovative Medical Technologies; Central Clinical Hospital of Russian Railways-Medicine; A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Russian Federation
Denis Sergeevich Romanov
22B Dukhovskoy pereulok, Moscow 115191
2 Budayskaya St., Moscow 129128
20/1 Delegatskaya St., Moscow 127473
N. V. Lasunin
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
Russian Federation
Russian Federation
16 4th Tverskaya-Yamskaya St., Moscow 125047
D. A. Balaeva
Central Clinical Hospital of Russian Railways-Medicine; A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Russian Federation
2 Budayskaya St., Moscow 129128
20/1 Delegatskaya St., Moscow 127473
M. P. Kazakov
Center for Innovative Medical Technologies
Russian Federation
Russian Federation
22B Dukhovskoy pereulok, Moscow 115191
References
1. Are C., Shaha A.R. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13(4):453–64. DOI: 10.1245/ASO.2006.05.042
2. Smallridge R.C., Ain K.B., Asa S.L. et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012;22(11):1104–39. DOI: 10.1089/ thy.2012.0302. DOI: 10.1089/thy.2012.0302
3. Untch B.R., Olson J.A. Jr. Anaplastic thyroid carcinoma, thyroid lymphoma, and metastasis to thyroid. Surg Oncol Clin N Am 2006;15(3):661–79. DOI: 10.1016/j.soc.2006.05.006
4. Sherman S.I. Anaplastic carcinoma: clinical aspects. In: Thyroid cancer: a comprehensive guide to clinical management. Ed. by L. Wartofsky, D. Van Nostrand. 2nd edn. Totowa: Humana Press, 2006. Pp. 629–632.
5. Venkatesh Y.S., Ordonez N.G., Schultz P.N. et al. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66(2):321–30. DOI: 10.1002/1097-0142(19900715)66:23.0.co;2-a
6. Пылев А.Л., Жандарова А.А., Петров К.С. и др. Анапластический рак щитовидной железы. Есть ли свет в конце туннеля? Опухоли головы и шеи 2020;10(1):10–9. DOI: 10.17650/2222- 1468-2020-10-1-10-19 Pylev А.L., Zhandarova А.А., Petrov К.S. et al. Anaplastic thyroid cancer. Is there a light at the end of the tunnel? Opukholi golovy i shei = Head and Neck Tumors 2020;10(1):10–9. (In Russ.). DOI: 10.17650/2222-1468-2020-10-1-10-19
7. Никифорович П.А., Румянцев П.О., Слепцов И.В. и др. Лечение BRAFV600E-позитивного рака щитовидной железы. Клиническое наблюдение. Сибирский онкологический журнал 2020;19(5):131–44. DOI: 10.21294/1814-4861-2020-19-5-131-144 Nikiforovich P.A., Rumyantsev P.O., Sleptsov I.V. et al. Treatment of BRAFV600E-positive thyroid cancer. Clinical observation. Sibirskii onkologicheskii zhurnal = Siberian Journal of Oncology 2020;19(5): 131–44. (In Russ.). DOI: 10.21294/1814-4861-2020-19-5-131-144
8. Subbiah V., Kreitman R.J., Wainberg Z.A. et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 2018;36(1):7–13. DOI: 10.1200/JCO.2017.73.6785
9. Marabelle A., Fakih M., Lopez J. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21(10):1353–65. DOI: 10.1016/S1470- 2045(20)30445-9
10. Capdevila J., Wirth L.J., Ernst T. et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol 2020;38(23):2620–7. DOI: 10.1200/JCO.19.02727
11. Ma M., Lin B., Wang M. et al. Immunotherapy in anaplastic thyroid cancer. Am J Transl Res 2020;12(3):974–88.
12. Zwaenepoel K., Jacobs J., De Meulenaere A. et al. CD70 and PD-L1 in anaplastic thyroid cancer-promising targets for immunotherapy. Histopathology 2017;71(3):357–65. DOI: 10.1111/his.13230
13. Cantara S., Bertelli E., Occhini R. et al. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine 2019;64(1):122–9. DOI: 10.1007/s12020-019-01865-5
14. Tuccilli C., Baldini E., Sorrenti S. et al. CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers. Int J Endocrinol 2018;2018:1742951. DOI: 10.1155/2018/1742951
15. Bible K.C., Kebebew E., Brierley J. et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2021;31(3):337386. DOI: 10.1089/ thy.2020.0944
16. Chiu A.C., Delpassand E.S., Sherman S.I. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82(11):3637–42. DOI: 10.1210/jcem.82.11.4386
17. Salvati M., Frati A., Rocchi G. et al. 2001 Single brain metastasis from thyroid cancer: report of twelve cases and review of the literature. J Neurooncol 51(1):33–40. DOI: 10.1023/a:1006468527935
18. D’Andrea M.A., Reddy G.K. Systemic antitumor effects and abscopal responses in melanoma patients receiving radiation therapy. Oncology 2020;98(4):202–15. DOI: 10.1159/000505487
Review
For citations:
Pylev A.L., Romanov D.S., Lasunin N.V., Balaeva D.A., Kazakov M.P. Anaplastic thyroid cancer: current capabilities of an oncologist. Head and Neck Tumors (HNT). 2023;13(1):116-125. (In Russ.) https://doi.org/10.17650/2222-1468-2023-13-1-116-125
Views:
296
Email this article 